Tags

Type your tag names separated by a space and hit enter

Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A(H1N1) 2009 pandemic in the Asia-Pacific region, March 2009 to March 2010.
Euro Surveill 2011; 16(3)ES

Abstract

During the first year of the influenza A(H1N1) 2009 pandemic, unprecedented amounts of the neuraminidase inhibitors, predominantly oseltamivir, were used in economically developed countries for the treatment and prophylaxis of patients prior to the availability of a pandemic vaccine. Due to concerns about the development of resistance, over 1,400 influenza A(H1N1) 2009 viruses isolated from the Asia-Pacific region during the first year of the pandemic (March 2009 to March 2010) were analysed by phenotypic and genotypic assays to determine their susceptibility to the neuraminidase inhibitors. Amongst viruses submitted to the World Health Organization Collaborating Centre for Reference and Research in Melbourne, Australia,oseltamivir resistance was detected in 1.3% of influenza A(H1N1) 2009 strains from Australia and 3.1% of strains from Singapore, but none was detected in specimens received from other countries in Oceania or south-east Asia, or in east Asia. The overall frequency of oseltamivir resistance in the Asia-Pacific region was 16 of 1,488 (1.1%). No zanamivir-resistant viruses were detected. Of the 16 oseltamivir-resistant isolates detected, nine were from immunocompromised individuals undergoing oseltamivir treatment and three were from immunocompetent individuals undergoing oseltamivir treatment. Importantly, four oseltamivir-resistant strains were from immunocompetent individuals who had not been treated with oseltamivir, demonstrating limited low-level community transmission of oseltamivir-resistant strains. Even with increased use of oseltamivir during the pandemic, the frequency of resistance has been low, with little evidence of community-wide spread of the resistant strains. Nevertheless, prudent use of the neuraminidase inhibitors remains necessary, as does continued monitoring for drug-resistant influenza viruses.

Authors+Show Affiliations

WHO Collaborating Centre for Reference and Research on Influenza, North Melbourne, Victoria, Australia. aeron.hurt@influenzacentre.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21262183

Citation

Hurt, A C., et al. "Oseltamivir-resistant Influenza Viruses Circulating During the First Year of the Influenza A(H1N1) 2009 Pandemic in the Asia-Pacific Region, March 2009 to March 2010." Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, vol. 16, no. 3, 2011.
Hurt AC, Deng YM, Ernest J, et al. Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A(H1N1) 2009 pandemic in the Asia-Pacific region, March 2009 to March 2010. Euro Surveill. 2011;16(3).
Hurt, A. C., Deng, Y. M., Ernest, J., Caldwell, N., Leang, L., Iannello, P., ... Barr, I. G. (2011). Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A(H1N1) 2009 pandemic in the Asia-Pacific region, March 2009 to March 2010. Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, 16(3).
Hurt AC, et al. Oseltamivir-resistant Influenza Viruses Circulating During the First Year of the Influenza A(H1N1) 2009 Pandemic in the Asia-Pacific Region, March 2009 to March 2010. Euro Surveill. 2011 Jan 20;16(3) PubMed PMID: 21262183.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A(H1N1) 2009 pandemic in the Asia-Pacific region, March 2009 to March 2010. AU - Hurt,A C, AU - Deng,Y M, AU - Ernest,J, AU - Caldwell,N, AU - Leang,L, AU - Iannello,P, AU - Komadina,N, AU - Shaw,R, AU - Smith,D, AU - Dwyer,D E, AU - Tramontana,A R, AU - Lin,R T, AU - Freeman,K, AU - Kelso,A, AU - Barr,I G, Y1 - 2011/01/20/ PY - 2011/1/26/entrez PY - 2011/1/26/pubmed PY - 2011/3/23/medline JF - Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin JO - Euro Surveill. VL - 16 IS - 3 N2 - During the first year of the influenza A(H1N1) 2009 pandemic, unprecedented amounts of the neuraminidase inhibitors, predominantly oseltamivir, were used in economically developed countries for the treatment and prophylaxis of patients prior to the availability of a pandemic vaccine. Due to concerns about the development of resistance, over 1,400 influenza A(H1N1) 2009 viruses isolated from the Asia-Pacific region during the first year of the pandemic (March 2009 to March 2010) were analysed by phenotypic and genotypic assays to determine their susceptibility to the neuraminidase inhibitors. Amongst viruses submitted to the World Health Organization Collaborating Centre for Reference and Research in Melbourne, Australia,oseltamivir resistance was detected in 1.3% of influenza A(H1N1) 2009 strains from Australia and 3.1% of strains from Singapore, but none was detected in specimens received from other countries in Oceania or south-east Asia, or in east Asia. The overall frequency of oseltamivir resistance in the Asia-Pacific region was 16 of 1,488 (1.1%). No zanamivir-resistant viruses were detected. Of the 16 oseltamivir-resistant isolates detected, nine were from immunocompromised individuals undergoing oseltamivir treatment and three were from immunocompetent individuals undergoing oseltamivir treatment. Importantly, four oseltamivir-resistant strains were from immunocompetent individuals who had not been treated with oseltamivir, demonstrating limited low-level community transmission of oseltamivir-resistant strains. Even with increased use of oseltamivir during the pandemic, the frequency of resistance has been low, with little evidence of community-wide spread of the resistant strains. Nevertheless, prudent use of the neuraminidase inhibitors remains necessary, as does continued monitoring for drug-resistant influenza viruses. SN - 1560-7917 UR - https://www.unboundmedicine.com/medline/citation/21262183/Oseltamivir_resistant_influenza_viruses_circulating_during_the_first_year_of_the_influenza_A_H1N1__2009_pandemic_in_the_Asia_Pacific_region_March_2009_to_March_2010_ L2 - http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19770 DB - PRIME DP - Unbound Medicine ER -